Acute lymphoblastic leukemia (ALL) is a hematological malignancy with a higher frequency in children than in adults. Adult ALL is associates with increased morbidity and mortality and a significantly lower survival rate compared to its pediatric counterpart with an average survival of 40% at 5 years. The prognosis of patients with ALL is determined by multiple factors, such as age, tumor syndrome, white blood cell counts, cytogenetic abnormalities, and therapeutic response. The Multiplex Ligation-dependent Probe Amplification technique (MLPA) is used to determine the copy number variations (CNV) of several key genes involved in disease progression and resistance, such as IKAROS family zinc finger 1 (IKZF1), PAX5, ETV6, RB1, BTG1, EBF1, CDKN2A/2B, CRLF2. In this study, we sought to investigate the relationship between these genetic markers and standard prognostic factors in a small cohort of adult ALL patients with the aim of improving our risk stratification strategies.